GENFIT (GNFT.PA) Stock Fundamental Analysis
Europe - EPA:GNFT - FR0004163111 - Common Stock
3.602 EUR
-0.01 (-0.22%)
Overall GNFT gets a fundamental rating of 4 out of 10. We evaluated GNFT against 73 industry peers in the Biotechnology industry. There are concerns on the financial health of GNFT while its profitability can be described as average. GNFT is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year GNFT was profitable.
GNFT had a positive operating cash flow in the past year.
In multiple years GNFT reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: GNFT reported negative operating cash flow in multiple years.
1.2 Ratios
GNFT's Return On Assets of 1.00% is fine compared to the rest of the industry. GNFT outperforms 71.62% of its industry peers.
With a decent Return On Equity value of 2.18%, GNFT is doing good in the industry, outperforming 75.68% of the companies in the same industry.
GNFT has a better Return On Invested Capital (3.45%) than 79.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1% | ||
| ROE | 2.18% | ||
| ROIC | 3.45% |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of GNFT (2.12%) is better than 74.32% of its industry peers.
In the last couple of years the Profit Margin of GNFT has declined.
GNFT has a better Operating Margin (4.55%) than 78.38% of its industry peers.
In the last couple of years the Operating Margin of GNFT has declined.
Looking at the Gross Margin, with a value of 97.11%, GNFT belongs to the top of the industry, outperforming 93.24% of the companies in the same industry.
In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.55% | ||
| PM (TTM) | 2.12% | ||
| GM | 97.11% |
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GNFT is destroying value.
GNFT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GNFT has been increased compared to 5 years ago.
GNFT has a worse debt/assets ratio than last year.
2.2 Solvency
GNFT has an Altman-Z score of -1.62. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
GNFT has a worse Altman-Z score (-1.62) than 60.81% of its industry peers.
The Debt to FCF ratio of GNFT is 4.26, which is a neutral value as it means it would take GNFT, 4.26 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of GNFT (4.26) is better than 79.73% of its industry peers.
GNFT has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
GNFT has a better Debt to Equity ratio (0.08) than 63.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 4.26 | ||
| Altman-Z | -1.62 |
ROIC/WACC0.49
WACC7.06%
2.3 Liquidity
A Current Ratio of 1.23 indicates that GNFT should not have too much problems paying its short term obligations.
The Current ratio of GNFT (1.23) is worse than 71.62% of its industry peers.
GNFT has a Quick Ratio of 1.23. This is a normal value and indicates that GNFT is financially healthy and should not expect problems in meeting its short term obligations.
GNFT has a Quick ratio of 1.23. This is in the lower half of the industry: GNFT underperforms 67.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 105.17% over the past year.
Measured over the past years, GNFT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -70.77% on average per year.
The Revenue has grown by 85.82% in the past year. This is a very strong growth!
GNFT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.61% yearly.
EPS 1Y (TTM)105.17%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-212.5%
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%
3.2 Future
The Earnings Per Share is expected to decrease by -29.14% on average over the next years. This is quite bad
The Revenue is expected to decrease by -0.27% on average over the next years.
EPS Next Y53.49%
EPS Next 2Y-94%
EPS Next 3Y-42.79%
EPS Next 5Y-29.14%
Revenue Next Year-6.23%
Revenue Next 2Y-22.29%
Revenue Next 3Y-5.19%
Revenue Next 5Y-0.27%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 120.07 indicates a quite expensive valuation of GNFT.
77.03% of the companies in the same industry are more expensive than GNFT, based on the Price/Earnings ratio.
GNFT is valuated expensively when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
GNFT is valuated cheaply with a Price/Forward Earnings ratio of 6.42.
Based on the Price/Forward Earnings ratio, GNFT is valued cheaper than 94.59% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.73, GNFT is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 120.07 | ||
| Fwd PE | 6.42 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GNFT is valued a bit cheaper than the industry average as 77.03% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of GNFT indicates a rather cheap valuation: GNFT is cheaper than 90.54% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.36 | ||
| EV/EBITDA | 32.42 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A cheap valuation may be justified as GNFT's earnings are expected to decrease with -42.79% in the coming years.
PEG (NY)2.24
PEG (5Y)N/A
EPS Next 2Y-94%
EPS Next 3Y-42.79%
5. Dividend
5.1 Amount
GNFT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:GNFT (9/12/2025, 7:00:00 PM)
3.602
-0.01 (-0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap180.11M
Analysts90.77
Price Target9.28 (157.63%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.87%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)924.96%
EPS NY rev (3m)924.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)-9.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 120.07 | ||
| Fwd PE | 6.42 | ||
| P/S | 2.54 | ||
| P/FCF | 12.36 | ||
| P/OCF | 11.58 | ||
| P/B | 2.6 | ||
| P/tB | 8.49 | ||
| EV/EBITDA | 32.42 |
EPS(TTM)0.03
EY0.83%
EPS(NY)0.56
Fwd EY15.57%
FCF(TTM)0.29
FCFY8.09%
OCF(TTM)0.31
OCFY8.63%
SpS1.42
BVpS1.38
TBVpS0.42
PEG (NY)2.24
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1% | ||
| ROE | 2.18% | ||
| ROCE | 4.23% | ||
| ROIC | 3.45% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 4.55% | ||
| PM (TTM) | 2.12% | ||
| GM | 97.11% | ||
| FCFM | 20.54% |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 4.26 | ||
| Debt/EBITDA | 1.12 | ||
| Cap/Depr | 56.79% | ||
| Cap/Sales | 1.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 314.19% | ||
| Profit Quality | 966.82% | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | -1.62 |
F-Score7
WACC7.06%
ROIC/WACC0.49
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.17%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-212.5%
EPS Next Y53.49%
EPS Next 2Y-94%
EPS Next 3Y-42.79%
EPS Next 5Y-29.14%
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%
Revenue Next Year-6.23%
Revenue Next 2Y-22.29%
Revenue Next 3Y-5.19%
Revenue Next 5Y-0.27%
EBIT growth 1Y112.1%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year67.69%
EBIT Next 3Y62.39%
EBIT Next 5YN/A
FCF growth 1Y125.16%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y128.05%
OCF growth 3Y-46.21%
OCF growth 5YN/A